Related Experiment Videos
Praziquantel, a new board-spectrum antischistosomal agent
Zeitschrift Fur Parasitenkunde (Berlin, Germany)
|July 21, 1977
Summary
Praziquantel is a potent antischistosomal drug effective against Schistosoma mansoni in mice, Mastomys, and hamsters. Optimal efficacy is achieved with fractional doses and against older worms, showing promise for treating schistosomiasis.
Area of Science:
- Pharmacology
- Parasitology
- Drug Efficacy Studies
Background:
- Schistosomiasis remains a significant global health concern, necessitating effective therapeutic agents.
- Praziquantel represents a key compound in the treatment of schistosomiasis.
Purpose of the Study:
- To evaluate the efficacy of praziquantel against Schistosoma mansoni in various host species.
- To determine optimal administration routes, schedules, and effective parasite stages for praziquantel treatment.
Main Methods:
- Administered praziquantel orally and via parenteral routes to mice, Mastomys, and Syrian hamsters infected with Schistosoma mansoni.
- Assessed parasite reduction based on varying doses, administration schedules (single vs. fractional doses), and worm age.
Main Results:
- Praziquantel demonstrated significant efficacy across all tested host species and administration routes.
- Fractional dosing regimens approximately doubled efficacy compared to single doses.
- Efficacy varied with parasite stage, being most potent against adult worms and less so against early juvenile forms.
Conclusions:
- Praziquantel is a highly effective antischistosomal agent with broad applicability.
- Optimizing dosing strategies and considering parasite developmental stage can enhance treatment outcomes for schistosomiasis.